BHVN - NYSE

Biohaven Ltd.

BHVN·NYSE

$10.81

+6.7%

HealthcareBiotechnology

Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on development of therapies for neurological and immunoscience diseases that can change current treatment paradigms.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$1.14B

EPS-6.8600

P/E Ratio-1.58

Earnings Date08/10/2026

bhvn

Cost of Revenue

Last Annual Value

4.14M

3-Year CAGR

5-Year CAGR

10-Year CAGR

Adjust for Inflation

Biohaven Ltd. Competitors Analysis of Cost of Revenue

BHVN · NYSE

Company	Cost of Revenue	CAGR 3Y	CAGR 5Y	CAGR 10Y
Biohaven Ltd. NYSE:BHVN	4.14M	N/A	N/A	N/A
Intellia Therapeutics, Inc. NASDAQ:NTLA	15.92M	21.1%	18.2%	-6.7%
Immunome, Inc. NASDAQ:IMNM	2.96M	N/A	N/A	N/A
Vera Therapeutics, Inc. NASDAQ:VERA	468.00K	N/A	N/A	N/A
Sionna Therapeutics, Inc. NASDAQ:SION	647.00K	N/A	N/A	N/A
Zenas BioPharma, Inc. NASDAQ:ZBIO	56.00K	N/A	N/A	N/A
Xeris Biopharma Holdings, Inc. NASDAQ:XERS	53.41M	23.1%	32.0%	141.2%
Celldex Therapeutics, Inc. NASDAQ:CLDX	0.00	N/A	N/A	N/A

Biohaven Ltd. Fair Value Envelope

BHVN · NYSE

Our analysis suggests that BHVN has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $10.81, this represents a potential HIDDEN relative to our calculated worth for Biohaven Ltd..

HIDDEN

Intrinsic Value

Current Price: $10.81

Related Guides

Blog Categories

Continue your BHVN research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.